Pulmonary artery smooth muscle cell (PA-SMC) proliferation and
inflammation are key components of
pulmonary arterial hypertension (PAH).
Interleukin (IL)-1β binds to
IL-1 receptor (R)1, thereby recruiting the molecular adaptor myeloid differentiation primary response
protein 88 (MyD88) (involved in IL-1R1 and
Toll-like receptor signal transduction) and inducing
IL-1,
IL-6 and tumour
necrosis factor-α synthesis through nuclear factor-κB activation.We investigated the IL-1R1/MyD88 pathway in the pathogenesis of
pulmonary hypertension.Marked IL-1R1 and MyD88 expression with predominant PA-SMC immunostaining was found in lungs from patients with idiopathic PAH, mice with
hypoxia-induced
pulmonary hypertension and SM22-5-HTT(+) mice. Elevations in lung IL-1β, IL-1R1, MyD88 and
IL-6 preceded
pulmonary hypertension in hypoxic mice. IL-1R1(-/-), MyD88(-/-) and control mice given the IL-1R1 antagonist
anakinra were protected similarly against hypoxic
pulmonary hypertension and perivascular macrophage recruitment.
Anakinra reversed
pulmonary hypertension partially in SM22-5-HTT(+) mice and markedly in
monocrotaline-treated rats. IL-1β-mediated stimulation of mouse PA-SMC growth was abolished by
anakinra and absent in IL-1R1(-/-) and MyD88(-/-) mice. Gene deletion confined to the myeloid lineage (M.lys-Cre MyD88(fl/fl) mice) decreased
pulmonary hypertension severity versus controls, suggesting IL-1β-mediated effects on PA-SMCs and macrophages. The growth-promoting effect of
media conditioned by M1 or M2 macrophages from M.lys-Cre MyD88(fl/fl) mice was attenuated.Pulmonary vessel remodelling and
inflammation during
pulmonary hypertension require IL-1R1/MyD88 signalling. Targeting the IL-1β/IL-1R1 pathway may hold promise for treating human PAH.